In one paragraphArticle in International journal of health policy and management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
29 authors.
Hamidreza JamaatiChronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.ORCID 0009-0005-0422-6087 Saeed KarimiDepartment of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3231-8414 Yunes PanahiChemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Shahnam ArshiCenter for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran.
Maryam HajimoradiLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-5147-3770 Fatemeh Sadat Hosseini-BaharanchiDepartment of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1633-2635 Fariba GhorbaniTracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-2090-204X Seyed Mohsen ZahraeiCenter for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran.
Fatemeh NouriLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7271-0202 Ali Akbari SariDepartment of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6933-4071 Mahshad GoharimehrDepartment of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-2898-8765 Abdolreza MohamadniaChronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.ORCID 0000-0001-9662-7462 Payam TabarsiClinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8932-5420 Farzaneh DastanChronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.ORCID 0000-0001-7253-4333 Babak Sharif-KashaniDepartment of Cardiology, Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3400-489X Majid MarjaniClinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-1466-8645 Farin Rashid FarokhiChronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6816-8753 Seyed Mohammad Reza HashemianChronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.ORCID 0000-0002-0768-9168 Mostafa NoorizadehDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Bulent Ecevit University, Zonguldak, Turkey.
Katayoun TayeriCenter for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran.ORCID 0000-0001-7153-1691 Sima NooraliLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7584-509X Farnaz AhmadiLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0009-0002-0713-0441 Makan SadrVirology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8781-8176 Azadeh MoradkhaniChronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran.
Mahdi AhmadiniaLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Bahamin AstaniLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rajabali DaroudiDepartment of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-0487-4114 Shadi ShafaghiLung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-9960-8854 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundThe global challenges posed by COVID-19 vaccinations require careful consideration by decision-makers at both the global and national levels, particularly in developing countries. This study aimed to evaluate the health and economic implications of implementing vaccination programs.
methodsTwo scenarios, one involving vaccination and the other without, were analyzed using the Markov susceptible-infectious-recovered (SIR) model. For the vaccination scenario, real-world data, such as age-specific vaccination coverage, hospitalization rates, and mortality, were obtained from the Medical Care Monitoring Center (MCMC) and national COVID-19 registry during the Omicron wave in Iran. For the counterfactual non-vaccination scenario, we relied on model-based assumptions using published literature and expert input to estimate infection rates and clinical outcomes in the absence of vaccination. The incremental cost-effectiveness ratio (ICER) of the COVID-19 vaccination program was calculated by comparing the incremental cost per unit of quality-adjusted life year (QALY) generated to a willingness-to-pay (WTP) threshold equivalent to 1 time the gross domestic product (GDP) per capita, approximately US$4091. One-way sensitivity analysis was conducted to ensure the reliability of the results.
resultsOverall, 2 098 495 extra QALYs were generated by vaccination, incurring a total extra cost of $853.78 million. The vaccination program resulted in an average of 0.035 incremental QALYs at an additional cost of $14.08 per person. The average ICER for adult vaccination was $406.85 per QALY, indicating that it is a highly cost-effective strategy compared to non-vaccination across all age groups. Vaccinating elderly individuals proved to be the most cost-effective approach among all age categories.
conclusionThe integrated Markov-SIR model used in this study provides valuable insights into both the health and economic impact of the COVID-19 vaccination program in Iran. These findings support the implementation of vaccination strategies and provide a framework for decision-makers to consider when formulating policies.
Indexed as
COVID-19COVID-19 VaccinesImmunization ProgramsMass VaccinationAdultCost-Benefit AnalysisCost-Effectiveness AnalysisHumansIranMarkov ChainsMiddle AgedQuality-Adjusted Life YearsCOVID-19 VaccinesCost-EffectivenessCOVID-19 VaccinationEconomic EvaluationICERIranQALY
Identifiers
PMID41966177
PMCPMC12958171
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390